Paulzk
Nov 19, 1:54 AM
$BCRX
Pfizer is undertaking yet another deal in China to get into a budding area of research, using "in vivo" cell therapy for autoimmune diseases.
Under the terms of the agreement with Starna Therapeutics, Pfizer will obtain exclusive rights outside Greater China to three preclinical programs focused on autoimmune diseases. It will also get the rights to use Starna's technology in inflammation, immunology and oncology as well as options to license other projects and expand its territory to include Greater China.
Pfizer will pay Starna
$330 million up front and offer as much as
$2.3 billion more in payments for reaching certain development and commercial milestones.
https://finance.yahoo.com/healthcare/articles/pfizer-leaps-vivo-car-t-155500147.html
0 replies